%0 Journal Article
%T Norcantharidin analogues: a patent review (2006 - 2010).
%A Deng L
%A Tang S
%J Expert Opin Ther Pat
%V 21
%N 11
%D Nov 2011
%M 22017412
%F 6.714
%R 10.1517/13543776.2011.629190
%X <B>BACKGROUND: </B>Norcantharidin (7-oxabicyclo [2.2.1] heptane-2,3-dicarboxylic anhydride) is the demethylated form of cantharidin. Norcantharidin not only has strong anticancer activity, but also eliminates most side-effects in the urinary system, does not cause myelosuppression and increases the number of white blood cells. With structural modification, norcantharidin analogues show potential anticancer activities.<BR><B>METHODS: </B>A comprehensive patent review of norcantharidin analogues from 2006 to 2010 is presented. Protein phosphatase 1, 2A, 2B and 5 inhibitors are described. The review summarizes the new compounds and lays the foundation for seeking more effective anticancer compounds.<BR><B>CONCLUSIONS: </B>Although norcantharidin has improved activity and toxicity, the effects routinely do not satisfy the current clinical need. Exploring better analogues is vital for changing the current situation, but norcantharidin is a good lead compound.